Back to search results

CIPN Decision Aid for Breast Cancer Patients

This study is looking at how a special tool called a CIPN DecisionAid can help breast cancer patients make choices about their chemotherapy treatment. CIPN (chemotherapy-induced peripheral neuropathy) is a common side effect of some cancer drugs, causing numbness or tingling in your hands or feet. These symptoms can get worse over time and affect your daily life. This study wants to see if using the CIPN DecisionAid helps you feel more prepared to make decisions about your treatment. You might be able to join if you have breast cancer, are currently on your third cycle of taxane treatment, and are experiencing any CIPN symptoms.

Study design
This interventional study plans to enroll 20 participants. The study is not specified as randomized or blinded.
What's involved
You would receive the CIPN DecisionAid and complete surveys. The primary endpoint is measured at up to 12 weeks.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at up to 12 weeks after the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06915168

CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer

Recruiting
NAAll AgesInterventionalSupportive care
University of Michigan Rogel Cancer Center
~20 participants
Updated 2026-04-08 on ClinicalTrials.gov
What's tested:Informational InterventionSurvey Administration

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in decision preparedness
Measured over up to 12 weeks

Conditions

Breast Carcinoma

Explore related trials

Breast Carcinoma

Where it's being run

1 sites across 1 states
Michigan1

Study leadership

  • Daniel L Hertz · PRINCIPAL_INVESTIGATOR · University of Michigan Rogel Cancer Center

Who to contact

Daniel Hertz
[email protected]
734-763-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with breast cancer
Currently receiving cycle three of taxane treatment
Approval of medical oncologist to enroll patient
Experiencing any CIPN based on enrollment screening question, "In the last 7 days, what was the severity of your numbness or tingling in your hands or feet at its worst? None, Mild, Moderate, Severe, Very Severe. Patient is eligible if their answer is anything except "None"
Access to a smartphone or similar device that can complete CIPN DecisionAid via Qualtrics while in the waiting room

Exclusion

Inability to read or speak English

What this trial measures

  • Change in decision preparednessup to 12 weeks

    Will be assessed using Question #2 on the Awareness, Preparedness, and Confidence Survey.